Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A Randomized Phase II Study of GDC-0068, an Inhibitor to Akt, in Combination with Fluoropyrimidine Plus Oxaliplatin Chemotherapy (mFOLFOX6) in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. ESTUDIO ALEATORIZADO, EN FASE II, CON GDC 0068, UN INHIBIDOR DE AKT, EN COMBINACIÓN CON UNA FLUOROPIRIMIDINA MÁS QUIMIOTERAPIA DE OXALIPLATINO (mFOLFOX6) EN PACIENTES CON CANCER LOCALMENTE AVANZADO O GASTRICO METASTÁSICO DE LA UNIÓN GASTROESOFÁGICA https://kusajili.fr:443/Trial/bZxUsUttm0im9Hzt3fm_SA%24a-randomized-phase-ii-study-of-gdc-0068-an-inhibitor-to-akt-in-combination-with-fluoropyrimidine-plus-oxaliplatin-chemotherapy-
I have read and accept the terms of use of the site and the Privacy Policy
Send your message